Drug intelligence / Profile preview

cisplatin + cyclophosphamide + edatrexate

Development stage: Unknown
Lead developer: Michigan State University
Modality: Small Molecules
Administration: Intravenous

Overview

This combination involves **cisplatin**, a platinum-based antineoplastic agent that interferes with DNA replication; **cyclophosphamide**, an alkylating agent that damages DNA; and **edatrexate**, a folate antagonist similar to methotrexate, used in cancer treatment. The combination is likely used for its synergistic effects in treating certain cancers.

Targets

DHFR (Dihydrofolate reductase)DNA

Beyond the preview

Go deeper on cisplatin + cyclophosphamide + edatrexate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on cisplatin + cyclophosphamide + edatrexate.

Explore the full profile